Three- and 6-month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite® drug-eluting stent: The ANCHOR study.
Rishi PuriImanol OtaeguiManel SabatéAntonio Serra-PeñarandaMarti PuigfelArmando Perez de PradoLuis Nombela-FrancoJose M de la Torre HernandezRosario Ortas NadalAndres Iniguez-RomoGustavo JiménezFelipe Fernandez-VazquezCarlos Cuellas-RamonNieves GonzaloVictor Alfonso Jiménez DiazLluis DuocastellaMaria MolinaMarc AmorosIsabel PerezAlberto Barria PerezEmilie Pelletier BeaumontStephen J NichollsBruno Garcia Del BlancoJosep Rodés-CabauPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2017)
At 6 months, the Angiolite DES was safe with high rates of strut coverage, modest degrees of neointimal hyperplasia and very low rates of strut malapposition. These data coupled with the absence of in-stent binary restenosis and a very low 6-month in-stent LLL point towards an efficacious DES. Future studies are required to evaluate its efficacy in broader lesion subsets with longer follow-up.
Keyphrases
- percutaneous coronary intervention
- public health
- acute coronary syndrome
- coronary artery disease
- acute myocardial infarction
- st segment elevation myocardial infarction
- ionic liquid
- current status
- heart failure
- peripheral blood
- atrial fibrillation
- coronary artery bypass grafting
- vascular smooth muscle cells
- antiplatelet therapy
- deep learning
- case control
- health insurance